Elanco Galliprant (grapiprant) 100mg

Galliprant is a specialized non-steroidal anti-inflammatory drug (NSAID) designed specifically for dogs to manage pain and inflammation associated with osteoarthritis. It has gained recognition in the veterinary field for its targeted approach, specifically acting as a prostaglandin receptor antagonist (PRA) that spares certain physiological functions common in older NSAID classes.

Historically, the product's development involves a collaboration between Aratana Therapeutics and Elanco Animal Health. While the research and development originated in the United States, manufacturing is handled through a global supply chain often utilizing facilities in the United States and specialized pharmaceutical manufacturing hubs in Europe or Asia.

Today, Galliprant is a core product within the Elanco Animal Health portfolio. Elanco, originally a subsidiary of the American pharmaceutical giant Eli Lilly and Company, became a fully independent, publicly traded entity in 2019. Headquartered in Indiana, USA, Elanco is one of the world's largest animal health companies, focused on providing innovative solutions to prevent and treat disease in livestock and pets.